Check Congress

Bill · 119th Congress

H.R. 1266

Combating Illicit Xylazine Act

Passed HouseIntroduced Feb 12, 2025Topic: Crime and Law Enforcement →
  1. 01 Introduced
  2. 02 Committee
  3. 03 Passed House
  4. 04 Passed Senate
  5. 05 To President
  6. 06 Law

Latest action · Sep 16, 2026
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.

Read the bill text · Placed on Calendar Senate ↗PDF ↗Congress.gov ↗
SummaryVotes 0Timeline 18Cosponsors 114Details

What this bill does

Combating Illicit Xylazine Act

This bill regulates xylazine under the Controlled Substances Act (CSA).

Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.

This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.

Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.

The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.

The bill also exempts xylazine manufacturers from the CSA's physical security requirements.

Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.

Congressional Research Service · Introduced in House · Feb 12, 2025

How Congress voted

No recorded votes yet. Many bills pass by voice vote or unanimous consent, where no one's individual vote is written down.

Timeline

  1. Sep 16, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
  2. Sep 15, 2026Motion to reconsider laid on the table Agreed to without objection.
  3. Sep 15, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)
  4. Sep 15, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  5. Sep 15, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.
  6. Sep 15, 2026Considered under suspension of the rules. (consideration: CR H5671-5673)
  7. Sep 15, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  8. Sep 14, 2026Placed on the Union Calendar, Calendar No. 715.
  9. Sep 14, 2026Committee on the Judiciary discharged.
  10. Sep 14, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I.
  11. Jul 21, 2026Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
  12. Jul 21, 2026Committee Consideration and Mark-up Session Held
  13. Jul 20, 2026Committee Consideration and Mark-up Session Held
  14. Jun 25, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
  15. Jun 25, 2026Subcommittee Consideration and Mark-up Session Held
  16. Feb 12, 2025Referred to the Subcommittee on Health.
  17. Feb 12, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  18. Feb 12, 2025Introduced in House

Cosponsors

114 members

Show all 114

Details

Related bills

S. 545On Congress.gov ↗Related

Cost estimates · Congressional Budget Office

None published

Subject tags · 9

Congressional oversightConsumer affairsCriminal procedure and sentencingDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsManufacturingU.S. Sentencing CommissionVeterinary medicine and animal diseases